预测和诊断纤维狭窄型克罗恩病的生物标志物:系统综述
该研究系统综述了截至2020年7月6日关于肠道纤维化生物标志物的文献,纳入使用全层组织病理学或横断面影像或内镜作为参考标准的研究。
要点
- 有前景的标志物包括COMP(AUC 0.805)、HGFA(AUC 0.738)和低miR-19-3p(AUC 0.67)。
- 多种抗鞭毛蛋白抗体与狭窄相关:A4-Fla2 OR 3.41,anti-Fla-X OR 2.95。
核心结论
- 缺乏关于肠道狭窄生物标志物的明确定义研究,开发可靠准确的狭窄生物标志物是研究优先事项。
研究设计与样本
- 系统综述检索PubMed、EMBASE、ISI Web of Science、Cochrane Library和Scopus截至2020年7月6日的文献,纳入使用全层组织病理学或横断面影像或内镜作为参考标准的研究。
主要发现
- 有前景的标志物包括软骨寡聚基质蛋白(AUC 0.805)、肝细胞生长因子激活因子(AUC 0.738)和低水平microRNA-19-3p(AUC 0.67)。
- 多种抗鞭毛蛋白抗体与狭窄相关:A4-Fla2(OR 3.41)、anti-Fla-X(OR 2.95)和anti-CBir1(多重)。
- 观察到显著异质性,且没有任何标志物经过正式验证。
关键数值与推荐
- 软骨寡聚基质蛋白AUC为0.805,肝细胞生长因子激活因子AUC为0.738,microRNA-19-3p AUC为0.67。
- A4-Fla2的OR为3.41,anti-Fla-X的OR为2.95。
临床怎么用
- 生物标志物可支持克罗恩病患者的临床管理,并有助于在未来抗纤维化药物临床试验中对患者进行分层和监测。
局限性
- 未能使用狭窄性疾病的标准化定义,缺乏特异性,与肠道狭窄发病机制的相关性不足,或对其操作特性了解不完整。
- 显著异质性,且没有标志物经过正式验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Intestinal strictures are a common complication of Crohn's disease (CD). Biomarkers of intestinal strictures would assist in their prediction, diagnosis, and monitoring. Herein we provide a comprehensive systematic review of studies assessing biomarkers that may predict or diagnose CD-associated strictures. METHODS: We performed a systematic review of PubMed, EMBASE, ISI Web of Science, Cochrane Library, and Scopus to identify citations pertaining to biomarkers of intestinal fibrosis through July 6, 2020, that used a reference standard of full-thickness histopathology or cross-sectional imaging or endoscopy. Studies were categorized based on the type of biomarker they evaluated (serum, genetic, histopathologic, or fecal). RESULTS: Thirty-five distinct biomarkers from 3 major groups were identified: serum (20 markers), genetic (9 markers), and histopathology (6 markers). Promising markers include cartilage oligomeric matrix protein, hepatocyte growth factor activator, and lower levels of microRNA-19-3p (area under the curves were 0.805, 0.738, and 0.67, respectively), and multiple anti-flagellin antibodies (A4-Fla2 [odds ratio, 3.41], anti Fla-X [odds ratio, 2.95], and anti-CBir1 [multiple]). Substantial heterogeneity was observed and none of the markers had undergone formal validation. Specific limitations to acceptance of these markers included failure to use a standardized definition of stricturing disease, lack of specificity, and insufficient relevance to the pathogenesis of intestinal strictures or incomplete knowledge regarding their operating properties. CONCLUSIONS: There is a lack of well-defined studies on biomarkers of intestinal stricture. Development of reliable and accurate biomarkers of stricture is a research priority. Biomarkers can support the clinical management of CD patients and aid in the stratification and monitoring of patients during clinical trials of future antifibrotic drug candidates.
引用
- Steiner CA, Berinstein JA, Louissaint J, et al. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2021. PMID: 34089850. doi:10.1016/j.cgh.2021.05.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。